Calidi Biotherapeutics (CLDI) Short term Debt (2022 - 2024)

Calidi Biotherapeutics (CLDI) posted quarterly Short term Debt of $223000.0 for Q4 2024, up 2.76% quarter-over-quarter from $217000.0 in Q3 2024.

Calidi Biotherapeutics (CLDI) Short term Debt (2022 - 2024) Analysis & Trends

Calidi Biotherapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $223000.0 for Q4 2024.

In Q4 2024, Short term Debt changed N/A year-over-year to $223000.0; the TTM figure through Dec 2024 stood at $223000.0 (changed N/A YoY), while the FY2024 annual figure was $223000.0, changed N/A from the prior year.
Short term Debt for Q4 2024 stood at $223000.0, up from $217000.0 in the prior quarter.
The five-year high for Short term Debt was $1.0 million in Q4 2022, with the low at $205000.0 in Q1 2024.
The 3-year median for Short term Debt is $220000.0 (2024), against an average of $476000.0.
Peak annual rise in Short term Debt reached 78.3% in 2024, while the deepest fall reached 78.3% in 2024.
Calidi Biotherapeutics' Short term Debt stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then sank by 77.7% to $223000.0 in 2024.
Business Quant data shows CLDI's Short term Debt at $223000.0 in Q4 2024, $217000.0 in Q3 2024, and $211000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Calidi Biotherapeutics	1.88 Mn	-2.22 Mn	-

Download Data